Good fat, bad fat: regulation of adipose tissue distribution

Obesity and associated metabolic outcomes define the metabolic syndrome, one of the most serious public health challenges. Yet, an under-appreciated fact is that body fat distribution, rather than total body fat amount, is a key determinant of metabolic disease. In contrast to upper-body obesity, lower-body fat accumulation inversely correlates with metabolic risks. Understanding processes regulating upper- vs. lower-body fat expansion is paramount to predict and combat these risks. Paradoxally, a hotspot mutation in nuclear lamin A causes rare partial lipodystrophies (FPLD2) leading to lower-body lipoatrophy, upper body fat accumulation and metabolic disorders; thus FPLD2 recapitulates features of obesity. Given our experience with FPLD2-linked adipocyte dysfunction, we propose FPLD2 as a model system to study obesity-linked metabolic disorders and fat depot-specific dysfunction. We combine functional studies, genomics, proteomics and clinical data analysis to identify mechanisms of depot-specific fat expansion and seek markers predicting metabolic outcomes of obesity. A main challenge is to what extent we can address the true relevance of the markers we will identify for metabolic risk. Importantly though, we dispose of preadipocytes from patient-paired abdominal and gluteal fat (native and immortalized), and using molecular and physiology measures, we will unveil new aspects of adipocyte biology relevant for obesity.


  • Samarbeid med Sykehus i Vestfold
  • UiO er forskningsansvarlig
  • Samarbeidsinstitusjon har behandlingsansvar for personopplysninger

Prosjektbeskrivelse med vedlegg

Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.


  • Nei
  • Begrunnelse: Ikke sensitive data


  • Lagret: Sykehus i Vestfold
  • Biobanknummer: REK 2018/660
  • Ansvarlig: Jens (Hertel)


NSD - Ja

Dokument ikke lastet opp

REK - Ja 1 fil

Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.

Statens legemiddelverk - Ikke behov

Prosjektleder / prosjektansvarlig ved UiO

Philippe Collas

Ansvarlig enhet

Seksjon for Biokjemi



  • Forskerprosjekt

Helsefaglig forskning

  • Ja


  • Ja


  • Start: juni 2018
  • Slutt: desember 2021